Cargando…

Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis

The anticancer activity of 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3) or calcitriol) has been widely reported in preclinical models. However, systematic investigation into the chemopreventive potential of calcitriol against the spectrum of oral carcinogenesis has not been performed. To address this g...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent-Chong, Vui King, DeJong, Hendrik, Attwood, Kristopher, Hershberger, Pamela A., Seshadri, Mukund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416727/
https://www.ncbi.nlm.nih.gov/pubmed/30875566
http://dx.doi.org/10.1016/j.neo.2019.02.002
_version_ 1783403415499440128
author Vincent-Chong, Vui King
DeJong, Hendrik
Attwood, Kristopher
Hershberger, Pamela A.
Seshadri, Mukund
author_facet Vincent-Chong, Vui King
DeJong, Hendrik
Attwood, Kristopher
Hershberger, Pamela A.
Seshadri, Mukund
author_sort Vincent-Chong, Vui King
collection PubMed
description The anticancer activity of 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3) or calcitriol) has been widely reported in preclinical models. However, systematic investigation into the chemopreventive potential of calcitriol against the spectrum of oral carcinogenesis has not been performed. To address this gap in knowledge, we conducted a preclinical prevention trial of calcitriol in the 4-nitroquinoline-1-oxide (4NQO) oral carcinogenesis model. C57BL/6 mice were exposed to the carcinogen 4NQO in drinking water for 16 weeks and randomized to control (4NQO only) or calcitriol arms. Calcitriol (0.1 μg i.p, Monday, Wednesday, and Friday) was administered for (i) 16 weeks concurrently with 4NQO exposure, (ii) 10 weeks post completion of 4NQO exposure, and, (iii) a period of 26 weeks concurrent with and following 4NQO exposure. Longitudinal magnetic resonance imaging (MRI) was performed to monitor disease progression until end point (week 26). Correlative histopathology of tongue sections was performed to determine incidence and multiplicity of oral dysplastic lesions and squamous cell carcinomas (SCC). Vitamin D metabolites and calcium were measured in the serum using liquid chromatography-mass spectrometry (LC–MS/MS) and colorimetric assay, respectively. Renal CYP24A1 (24-hydroxylase) and CYP27B1 (1α-hydroxylase) expression was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Immunostaining of tongue sections for vitamin D receptor (VDR), CYP24A1, and Ki67 was also performed. Non-invasive MRI enabled longitudinal assessment of lesions in the oral cavity. Calcitriol administered concurrently with 4NQO for 16 weeks significantly (P < .001) decreased the number of premalignant lesions by 57% compared to 4NQO only controls. Mice treated with calcitriol for 26 weeks showed highest renal CYP24A1, lowest serum 1,25(OH)(2)D(3) levels and highest incidence of invasive SCC. Immunohistochemistry revealed increased VDR, CYP24A1 and Ki67 staining in dysplastic epithelia compared to normal epithelium, in all four groups. Collectively, our results show that the effects of calcitriol on oral carcinogenesis are critically influenced by the stage of intervention and duration of exposure and provide the basis for exploring the potential of calcitriol for prevention of OSCC in the clinical setting.
format Online
Article
Text
id pubmed-6416727
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-64167272019-03-26 Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis Vincent-Chong, Vui King DeJong, Hendrik Attwood, Kristopher Hershberger, Pamela A. Seshadri, Mukund Neoplasia Original article The anticancer activity of 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3) or calcitriol) has been widely reported in preclinical models. However, systematic investigation into the chemopreventive potential of calcitriol against the spectrum of oral carcinogenesis has not been performed. To address this gap in knowledge, we conducted a preclinical prevention trial of calcitriol in the 4-nitroquinoline-1-oxide (4NQO) oral carcinogenesis model. C57BL/6 mice were exposed to the carcinogen 4NQO in drinking water for 16 weeks and randomized to control (4NQO only) or calcitriol arms. Calcitriol (0.1 μg i.p, Monday, Wednesday, and Friday) was administered for (i) 16 weeks concurrently with 4NQO exposure, (ii) 10 weeks post completion of 4NQO exposure, and, (iii) a period of 26 weeks concurrent with and following 4NQO exposure. Longitudinal magnetic resonance imaging (MRI) was performed to monitor disease progression until end point (week 26). Correlative histopathology of tongue sections was performed to determine incidence and multiplicity of oral dysplastic lesions and squamous cell carcinomas (SCC). Vitamin D metabolites and calcium were measured in the serum using liquid chromatography-mass spectrometry (LC–MS/MS) and colorimetric assay, respectively. Renal CYP24A1 (24-hydroxylase) and CYP27B1 (1α-hydroxylase) expression was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Immunostaining of tongue sections for vitamin D receptor (VDR), CYP24A1, and Ki67 was also performed. Non-invasive MRI enabled longitudinal assessment of lesions in the oral cavity. Calcitriol administered concurrently with 4NQO for 16 weeks significantly (P < .001) decreased the number of premalignant lesions by 57% compared to 4NQO only controls. Mice treated with calcitriol for 26 weeks showed highest renal CYP24A1, lowest serum 1,25(OH)(2)D(3) levels and highest incidence of invasive SCC. Immunohistochemistry revealed increased VDR, CYP24A1 and Ki67 staining in dysplastic epithelia compared to normal epithelium, in all four groups. Collectively, our results show that the effects of calcitriol on oral carcinogenesis are critically influenced by the stage of intervention and duration of exposure and provide the basis for exploring the potential of calcitriol for prevention of OSCC in the clinical setting. Neoplasia Press 2019-03-13 /pmc/articles/PMC6416727/ /pubmed/30875566 http://dx.doi.org/10.1016/j.neo.2019.02.002 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Vincent-Chong, Vui King
DeJong, Hendrik
Attwood, Kristopher
Hershberger, Pamela A.
Seshadri, Mukund
Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
title Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
title_full Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
title_fullStr Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
title_full_unstemmed Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
title_short Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
title_sort preclinical prevention trial of calcitriol: impact of stage of intervention and duration of treatment on oral carcinogenesis
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416727/
https://www.ncbi.nlm.nih.gov/pubmed/30875566
http://dx.doi.org/10.1016/j.neo.2019.02.002
work_keys_str_mv AT vincentchongvuiking preclinicalpreventiontrialofcalcitriolimpactofstageofinterventionanddurationoftreatmentonoralcarcinogenesis
AT dejonghendrik preclinicalpreventiontrialofcalcitriolimpactofstageofinterventionanddurationoftreatmentonoralcarcinogenesis
AT attwoodkristopher preclinicalpreventiontrialofcalcitriolimpactofstageofinterventionanddurationoftreatmentonoralcarcinogenesis
AT hershbergerpamelaa preclinicalpreventiontrialofcalcitriolimpactofstageofinterventionanddurationoftreatmentonoralcarcinogenesis
AT seshadrimukund preclinicalpreventiontrialofcalcitriolimpactofstageofinterventionanddurationoftreatmentonoralcarcinogenesis